Atherosclerotic cardiovascular diseases (ASCVD) are preferential targets of preventive medicine partially through therapies to improve atherogenic lipid profiles. The aim of the present work was to test a novel nutraceutical formulation (CSN) for its potential effects on plasma triglyceride levels of healthy subjects with moderate dyslipidemia. A cohort of 52 individuals were administered daily, for 8 weeks, with four gastro-resistant capsules of CSN, each one containing 500 mg of cryo-micronized chia seeds and 15 mg of vitamin E, according to a single centre, randomized, placebo controlled, 16 weeks trial. Data showed the following mean lipid changes: triglycerides, −27.5% (P = .0095); total cholesterol, −8.0% (P = .0019); High Density Lipoprotein cholesterol, +5.7% (P = .0042); Low Density Lipoprotein cholesterol, −10.2% (P = .0021). CSN may be regarded as a novel complementary and/or alternative safe remedy with clinical relevance in the primary cardiovascular disease prevention.

动脉粥样硬化性心血管疾病（ASCVD）部分地通过疗法来改善动脉粥样硬化性脂质状况，是预防医学的优先目标。本工作的目的是测试一种新型的营养保健品配方（CSN）对中度血脂异常的健康受试者血浆甘油三酸酯水平的潜在影响。根据一个单一的，随机，安慰剂对照的中心研究，每天对一组52人进行为期8周的治疗，共服用4种CSN耐胃溃疡的CSN胶囊，每个胶囊包含500 mg冷冻微粉化的正大种子和15 mg维生素E。 ，试用16周。数据显示以下平均脂质变化：甘油三酸酯，-27.5％（P  = .0095）；总胆固醇-8.0％（P  = .0019）; 高密度脂蛋白胆固醇，+ 5.7％（P = .0042）; 低密度脂蛋白胆固醇，-10.2％（P  = .0021）。CSN可以被认为是在初级心血管疾病预防中具有临床意义的新颖的补充和/或替代安全治疗方法。